Lilly Signs a Global Research and License Collaboration with Dicerna for ~$550M

Shots:

• Dicerna will receive $100M upfront plus ~$350M as development and commercialization milestones with tiered royalties and equity investment of $100M
• Lilly will get hold of Dicerna’s GalXC RNAi technology as well as development and commercialization rights to new developed drugs in fields of cardio-metabolic diseases, neurodegeneration and pain
• Dicerna’s GalXC RNAi technology is an attempt to enhance development of next-generation RNAi-based therapeutics, with SC delivery of therapies across multiple therapy areas, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases

 Click here to read full press release/ article | Ref: Eli Lilly | Image: Drug Delivery Business